Sodium-glucose cotransporter-2 inhibitors in heart failure. How durable is the decongestive effect?
Abstract
This Editorial Comment refers to ‘Short- and mid-term effects of empagliflozin on sodium balance and fluid regulation in chronic heart failure’, by V. Bytyqi et al., https://doi.org/10.1002/ejhf.70078. Sodium-glucose cotransporter-2 inhibitors (SGLT-2i) have become a class I-recommended group of drugs for heart failure (HF) patients across the entire left ventricular ejection fraction (EF) spectrum.1,2 Although the effect of the drugs on hard clinical outcomes (a composite of mortality and HF hospitalizations) has been demonstrated, we still do not know the exact mechanism underlying the tremendous clinical success.3 As SGLT2 transporters are expressed in numerous cell types, including proximal renal tubule cells, and their inhibition leads to glucosuria, thus a diuretic effect should be considered as one of the potential physiological consequences.4 The early results of the EMPA-RESPONSE-AHF trial, which recruited 80 decompensated HF patients and randomized them to receive empagliflozin vs. placebo, showed higher cumulative urine output through day 4 [the difference of 3449 (95% CI 578–6321) mL, n = 28].5 This was followed by the mechanistic substudy, which aimed to provide information on electrolyte and glucose handling in patients exposed to SGLT2i. Empagliflozin led to a significant increase in the fractional excretion of glucose, accompanied by an increase in serum osmolarity without affecting fractional sodium excretion.6 In another mechanistic study, the initiation of…
How strong is the evidence?
Evidence Hub reads this as a randomized trial, done in people. Its evidence level is 2 of 5 (High · randomized trial). Randomized trials of a reasonable size are the strongest single-study design. Reported size: 80 participants or records.
Read the paper
Related studies
- Strategy for Mitigating DKA Risk in Patients with Type 1 Diabetes on Adjunctive Treatment with SGLT Inhibitors: A STICH Protocol
- Glucoraphanin: a broccoli sprout extract that ameliorates obesity-induced inflammation and insulin resistance
- SGLT2 Inhibitors in Heart Failure: Targeted Metabolomics and Energetic Metabolism
- Mechanisms of blood pressure reduction with sodium-glucose co-transporter 2 (SGLT2) inhibitors
- Sodium-glucose cotransporter inhibitors: beyond glycaemic control
- Decoding the effects of SGLT2 inhibitors on cardiac arrhythmias in heart failure
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.